Pfizer Reduces BioNTech Holding by 54.7% While Collaboration Remains Intact
Pfizer Inc. (NYSE: PFE) disclosed on November 13, 2025 that it has sold a portion of its...
NASDAQ: BNTX
Pfizer‑BioNTech Receives FDA Approval for New COVID‑19 Vaccine Indication for High‑Risk Adults
Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) today announced that the United States...
CureVac and GSK Resolve mRNA Vaccine Patent Dispute With BioNTech and Pfizer
CureVac N.V. (NASDAQ: CVAC) announced on August 7, 2025, that it has reached an agreement...
Pfizer and BioNTech’s LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod
US giant Pfizer Inc., (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) announced today that...
BioNTech in Deal to Acquire CureVac for $1.25B to Boost Cancer mRNA Therapies
Germany-based BioNTech SE (NASDAQ: BNTX) announced plans to acquire all outstanding shares of fellow German...
BioNTech Partners with BMS to Jointly Develop BNT327 for Solid Tumors
Germany-based BioNTech SE (NASDAQ: BNTX) announced a strategic partnership with US major Bristol-Myers Squibb (BMS,...
Duality Biologics’ DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial
Duality Biologics, in partnership with BioNTech (NASDAQ: BNTX), has announced the initial data from the...
BioNTech Acquires Biotheus for $800 Million, Enhancing Oncology Pipeline
BioNTech (NASDAQ: BNTX), the biotech giant recognized for its role in developing the COVID-19 vaccine,...
BioNTech Seals Acquisition of China’s Biotheus for Up to $950M
China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ:...
Genmab CEO Signals Potential for China Partnership as BioNTech Exits acasunlimab Collaboration
COPENHAGEN—In a strategic pivot following BioNTech (NASDAQ: BNTX)’s withdrawal from their co-development partnership on the...
BioNTech’s BNT326/YL202 Clears FDA Hurdle, Advancing in Clinical Trials for Solid Tumor Treatment
FRANKFURT—BioNTech SE (NASDAQ: BNTX), a leading German biotechnology company, has announced that the US Food...
BioNTech Ends Collaboration with Genmab on Acasunlimab Development
Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, has announced that its German partner BioNTech...
BioNTech’s mRNA Cancer Immunotherapy BNT111 Achieves Primary Endpoint in Phase II Trial
Germany-based BioNTech SE (NASDAQ: BNTX) has announced that its mRNA cancer immunotherapy BNT111, in combination...
China’s Triastek and Germany’s BioNTech Join Forces for 3D Printed Oral Therapeutics
Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a...
BioNTech and MediLink’s HER3 ADC BNT326 Faces Partial Clinical Hold in the US
BioNTech SE (NASDAQ: BNTX), a German biotechnology company, and its Chinese co-development partner MediLink Therapeutics...
BioNTech Secures Global Rights to Biotheus Inc.’s Pre-Clinical Bispecific Antibody
Biotheus Inc., a biopharmaceutical company based in China, has announced that its German partner BioNTech...
BioNTech Acquires Pre-Clinical Asset and ADC Technology from Portuguese Biotech CellmAbs
Germany’s BioNTech (NASDAQ: BNTX) has licensed a pre-clinical antibody candidate and additional antibody-drug conjugate (ADC)...
WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal
WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered...
Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC
Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...
BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal
Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based...